The biosimilar CPT-13 (Remsima) is currently approved in Europe for all uses for which the originator infliximab (Remicade) is approved, including Crohn disease (CD) and ulcerative colitis (UC), which are often referred to collectively as IBD.
An observational study found health-related quality of life and disease activity in Finnish patients on maintenance therapy for inflammatory bowel disease (IBD) were comparable before and after switching from infliximab to a biosimilar at one-third the cost.
The biosimilar CPT-13 (Remsima) is currently approved in Europe for all uses for which the originator infliximab (Remicade) is approved, including Crohn disease (CD) and ulcerative colitis (UC), which are often referred to collectively as IBD.
In this observational study, health-related quality of life (HRQoL) and disease activity were assessed in adult patients on maintenance therapy for IBD at the time of switching to the biosimilar and then twice more, at 3 and 12 months. The study included 54 patients with IBD: 26 with CD, 27 with UC, and 1 with unclassified IBD.
Health-related quality of life (HRQoL) was evaluated by a survey assessing 15 dimensions of health with possible scores ranging from 0 (death) to 1 (full health). Mean scores at 3 and 12 months did not significantly differ from time of switching in patients with CD or UC. However, in patients with CD, there was a significant decrease in 2 dimensions, breathing and excretion, from time of switching to 12 months. There were no significant differences in any dimension in UC. Of the entire study group, 40% of patients experienced a clinically important improvement, and 31% experienced a clinically important deterioration at 12 months.
Disease activity was assessed by questionnaires (Inflammatory Bowel Disease Questionnaire; IBDQ), clinical evaluation (Crohn Disease Activity Index; CDAI, or Partial Mayo Score; pMayo), and an objective laboratory measurement (fecal calprotectin; FC). In the whole study group, there were no statistically significant changes in these disease activity indicators between the time of switching and 3 months or 12 months.
At 3 months there was an improvement in IBDQ scores in patients with CD compared to time of switching, but the difference was no longer statistically significant at 12 months. A change in IBDQ score indicating a clinically meaningful improvement occurred in 1/26 patients with CD and 4/27 patients with UC at 12 months. One patient with UC experienced an IBDQ score change indicating relapse.
The authors concluded infliximab and biosimilar CPT-13 performed comparably for maintenance therapy of IBD during the 12 months of follow-up. Cost of the therapy, however, did differ. When comparing 1 year on infliximab and 1 year on the biosimilar, the number of drug administration visits and doses were not significantly different, but the cost of the biosimilar was 35% that of the originator. Costs related to secondary health care were not significantly different in the year on infliximab and the year on the biosimilar.
Reference
Huoponen S, Eberl A, Räsänen P, et al. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore). 2020;99(2):e18723. doi:10.1097/MD.0000000000018723.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.